Taken together, there is strong evidence that the gastrointestinal microbiome is altered in PD and this is similarly true for the composition of the intestinal metabolome. SCFAs are increasingly studied intestinal metabolites that have shown great potential to influence disease processes in neuroinflammatory disorders. Their role for neurodegenerative movement disorders such as PD is still unclear but both analyses in translational disease models and in human clinical trials are on the way to improve our understanding. CLICK TO REVIEW